Selected research
Industry Research
Drugs of UDCA Industry Research Report 2026
Market perspective
The global Drugs of UDCA market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Drugs of UDCA is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Drugs of UDCA is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Drugs of UDCA is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Drugs of UDCA include Teva, Shanghai Pharma, Mylan, Mitsubishi Tanabe Pharma, Lannett, Impax, Grindeks, Epic Pharma and Dr. Falk Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Drugs of UDCA market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drugs of UDCA Market by Company
Teva
Shanghai Pharma
Mylan
Mitsubishi Tanabe Pharma
Lannett
Impax
Grindeks
Epic Pharma
Dr. Falk Pharma
Daewoong Pharmaceutical
Bruschettini
Drugs of UDCA Segment by Type
Capsule
Tablet
Drugs of UDCA Segment by Application
Hepatopathy
Gallstone
Biliary Disease
Other
Drugs of UDCA Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs of UDCA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs of UDCA and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs of UDCA.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Drugs of UDCA manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Drugs of UDCA by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Drugs of UDCA in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Capsule
- Tablet
Applications
- Hepatopathy
- Gallstone
- Biliary Disease
- Other
Companies covered
- Teva
- Shanghai Pharma
- Mylan
- Mitsubishi Tanabe Pharma
- Lannett
- Impax
- Grindeks
- Epic Pharma
- Dr. Falk Pharma
- Daewoong Pharmaceutical
- Bruschettini
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Drugs of UDCA Market Size (2021-2032)
- 2.2.2 Global Drugs of UDCA Sales (2021-2032)
- 2.2.3 Global Drugs of UDCA Market Average Price (2021-2032)
- 2.3 Drugs of UDCA by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Capsule
- 2.3.3 Tablet
- 2.4 Drugs of UDCA by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hepatopathy
- 2.4.3 Gallstone
- 2.4.4 Biliary Disease
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Drugs of UDCA Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Drugs of UDCA Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Drugs of UDCA Revenue of Manufacturers (2021-2026)
- 3.4 Global Drugs of UDCA Average Price by Manufacturers (2021-2026)
- 3.5 Global Drugs of UDCA Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Drugs of UDCA, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Drugs of UDCA, Product Type & Application
- 3.8 Global Manufacturers of Drugs of UDCA, Established Date
- 3.9 Global Drugs of UDCA Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Drugs of UDCA Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Drugs of UDCA Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Shanghai Pharma
- 4.2.1 Shanghai Pharma Company Information
- 4.2.2 Shanghai Pharma Business Overview
- 4.2.3 Shanghai Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shanghai Pharma Drugs of UDCA Product Portfolio
- 4.2.5 Shanghai Pharma Recent Developments
- 4.3 Mylan
- 4.3.1 Mylan Company Information
- 4.3.2 Mylan Business Overview
- 4.3.3 Mylan Drugs of UDCA Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mylan Drugs of UDCA Product Portfolio
- 4.3.5 Mylan Recent Developments
- 4.4 Mitsubishi Tanabe Pharma
- 4.4.1 Mitsubishi Tanabe Pharma Company Information
- 4.4.2 Mitsubishi Tanabe Pharma Business Overview
- 4.4.3 Mitsubishi Tanabe Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mitsubishi Tanabe Pharma Drugs of UDCA Product Portfolio
- 4.4.5 Mitsubishi Tanabe Pharma Recent Developments
- 4.5 Lannett
- 4.5.1 Lannett Company Information
- 4.5.2 Lannett Business Overview
- 4.5.3 Lannett Drugs of UDCA Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lannett Drugs of UDCA Product Portfolio
- 4.5.5 Lannett Recent Developments
- 4.6 Impax
- 4.6.1 Impax Company Information
- 4.6.2 Impax Business Overview
- 4.6.3 Impax Drugs of UDCA Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Impax Drugs of UDCA Product Portfolio
- 4.6.5 Impax Recent Developments
- 4.7 Grindeks
- 4.7.1 Grindeks Company Information
- 4.7.2 Grindeks Business Overview
- 4.7.3 Grindeks Drugs of UDCA Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Grindeks Drugs of UDCA Product Portfolio
- 4.7.5 Grindeks Recent Developments
- 4.8 Epic Pharma
- 4.8.1 Epic Pharma Company Information
- 4.8.2 Epic Pharma Business Overview
- 4.8.3 Epic Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Epic Pharma Drugs of UDCA Product Portfolio
- 4.8.5 Epic Pharma Recent Developments
- 4.9 Dr. Falk Pharma
- 4.9.1 Dr. Falk Pharma Company Information
- 4.9.2 Dr. Falk Pharma Business Overview
- 4.9.3 Dr. Falk Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Dr. Falk Pharma Drugs of UDCA Product Portfolio
- 4.9.5 Dr. Falk Pharma Recent Developments
- 4.10 Daewoong Pharmaceutical
- 4.10.1 Daewoong Pharmaceutical Company Information
- 4.10.2 Daewoong Pharmaceutical Business Overview
- 4.10.3 Daewoong Pharmaceutical Drugs of UDCA Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Daewoong Pharmaceutical Drugs of UDCA Product Portfolio
- 4.10.5 Daewoong Pharmaceutical Recent Developments
- 4.11 Bruschettini
- 4.11.1 Bruschettini Company Information
- 4.11.2 Bruschettini Business Overview
- 4.11.3 Bruschettini Drugs of UDCA Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Bruschettini Drugs of UDCA Product Portfolio
- 4.11.5 Bruschettini Recent Developments
5 Global Drugs of UDCA Market Scenario by Region
- 5.1 Global Drugs of UDCA Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Drugs of UDCA Sales by Region: 2021-2032
- 5.2.1 Global Drugs of UDCA Sales by Region: 2021-2026
- 5.2.2 Global Drugs of UDCA Sales by Region: 2027-2032
- 5.3 Global Drugs of UDCA Revenue by Region: 2021-2032
- 5.3.1 Global Drugs of UDCA Revenue by Region: 2021-2026
- 5.3.2 Global Drugs of UDCA Revenue by Region: 2027-2032
- 5.4 North America Drugs of UDCA Market Facts & Figures by Country
- 5.4.1 North America Drugs of UDCA Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Drugs of UDCA Sales by Country (2021-2032)
- 5.4.3 North America Drugs of UDCA Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Drugs of UDCA Market Facts & Figures by Country
- 5.5.1 Europe Drugs of UDCA Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Drugs of UDCA Sales by Country (2021-2032)
- 5.5.3 Europe Drugs of UDCA Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Drugs of UDCA Market Facts & Figures by Country
- 5.6.1 Asia Pacific Drugs of UDCA Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Drugs of UDCA Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Drugs of UDCA Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Drugs of UDCA Market Facts & Figures by Country
- 5.7.1 South America Drugs of UDCA Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Drugs of UDCA Sales by Country (2021-2032)
- 5.7.3 South America Drugs of UDCA Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Drugs of UDCA Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Drugs of UDCA Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Drugs of UDCA Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Drugs of UDCA Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Drugs of UDCA Sales by Type (2021-2032)
- 6.1.1 Global Drugs of UDCA Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Drugs of UDCA Sales Market Share by Type (2021-2032)
- 6.2 Global Drugs of UDCA Revenue by Type (2021-2032)
- 6.2.1 Global Drugs of UDCA Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Drugs of UDCA Revenue Market Share by Type (2021-2032)
- 6.3 Global Drugs of UDCA Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Drugs of UDCA Sales by Application (2021-2032)
- 7.1.1 Global Drugs of UDCA Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Drugs of UDCA Sales Market Share by Application (2021-2032)
- 7.2 Global Drugs of UDCA Revenue by Application (2021-2032)
- 7.2.1 Global Drugs of UDCA Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Drugs of UDCA Revenue Market Share by Application (2021-2032)
- 7.3 Global Drugs of UDCA Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Drugs of UDCA Value Chain Analysis
- 8.1.1 Drugs of UDCA Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Drugs of UDCA Production Mode & Process
- 8.2 Drugs of UDCA Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Drugs of UDCA Distributors
- 8.2.3 Drugs of UDCA Customers
9 Global Drugs of UDCA Analyzing Market Dynamics
- 9.1 Drugs of UDCA Industry Trends
- 9.2 Drugs of UDCA Industry Drivers
- 9.3 Drugs of UDCA Industry Opportunities and Challenges
- 9.4 Drugs of UDCA Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst